000			01986 a2200565 4500
005			20250515103419.0
264		0	_c20080407
008			200804s 0 0 eng d
022			_a0959-4973
024	7		_a10.1097/CAD.0b013e3282f2885f _2doi
040			_aNLM _beng _cNLM
100	1		_aPang, Li-ping
245	0	0	_aSLXM-2, a derivative of cyclophosphamide: mechanism of growth inhibition on hepatocarcinoma 22 cells. _h[electronic resource]
260			_bAnti-cancer drugs _cFeb 2008
300			_a167-74 p. _bdigital
500			_aPublication Type: Journal Article; Research Support, Non-U.S. Gov't
650	0	4	_aAnimals
650	0	4	_aAntineoplastic Agents, Alkylating _xadministration & dosage
650	0	4	_aBlotting, Western
650	0	4	_aCDC2-CDC28 Kinases _xgenetics
650	0	4	_aCarcinoma, Hepatocellular _xdrug therapy
650	0	4	_aCell Line, Tumor
650	0	4	_aCell Proliferation _xdrug effects
650	0	4	_aCyclin B _xgenetics
650	0	4	_aCyclin B1
650	0	4	_aCyclophosphamide _xadministration & dosage
650	0	4	_aDose-Response Relationship, Drug
650	0	4	_aFlow Cytometry
650	0	4	_aG2 Phase _xdrug effects
650	0	4	_aGene Expression _xdrug effects
650	0	4	_aInjections, Intraperitoneal
650	0	4	_aLeukocyte Count
650	0	4	_aLiver Neoplasms, Experimental _xdrug therapy
650	0	4	_aMale
650	0	4	_aMice
650	0	4	_aMice, Inbred ICR
650	0	4	_aMolecular Structure
650	0	4	_aPiperazines _xadministration & dosage
650	0	4	_aRNA, Messenger _xgenetics
650	0	4	_aReverse Transcriptase Polymerase Chain Reaction
650	0	4	_aS Phase _xdrug effects
650	0	4	_aWeight Loss _xdrug effects
700	1		_aHuang, Wei
700	1		_aSun, Qi
700	1		_aGuo, Wei
700	1		_aLi, Run-tao
700	1		_aCui, Jing-rong
773	0		_tAnti-cancer drugs _gvol. 19 _gno. 2 _gp. 167-74
856	4	0	_uhttps://doi.org/10.1097/CAD.0b013e3282f2885f _zAvailable from publisher's website
999			_c17686464 _d17686464